ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.650,03
-1,38%
S&P 500
5.307,01
-0,27%
US Dollar vs BRL
5,1527
0,00%
Bitcoin
69.399,61
0,43%
Brent Oil
81,255
-0,34%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Edgewise Therapeutics Inc (EWTX)

  7. Edgewise Therapeutics Inc (EWTX) Notícias

EWTX

Edgewise Therapeutics (EWTX)

Edgewise Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EWTX
DataHoraFonteTítuloCódigoCompanhia
10/05/202410:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
10/05/202410:07Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EWTXEdgewise Therapeutics Inc
10/05/202409:00Business WireEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
09/05/202410:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EWTXEdgewise Therapeutics Inc
09/05/202409:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EWTXEdgewise Therapeutics Inc
09/05/202409:00Business WireEdgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
07/05/202410:16Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EWTXEdgewise Therapeutics Inc
07/05/202409:00Business WireEdgewise Therapeutics Appoints Arlene Morris to its Board of DirectorsNASDAQ:EWTXEdgewise Therapeutics Inc
06/05/202409:00Business WireEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)NASDAQ:EWTXEdgewise Therapeutics Inc
23/04/202409:00Business WireEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesNASDAQ:EWTXEdgewise Therapeutics Inc
15/04/202417:05Business WireEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)NASDAQ:EWTXEdgewise Therapeutics Inc
28/03/202409:00Business WireEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionNASDAQ:EWTXEdgewise Therapeutics Inc
27/03/202409:00Business WireEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
05/03/202410:00Business WireEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
28/02/202410:00Business WireEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceNASDAQ:EWTXEdgewise Therapeutics Inc
22/02/202410:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
22/02/202410:00Business WireEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
14/02/202410:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EWTXEdgewise Therapeutics Inc
13/02/202410:00Business WireEdgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)NASDAQ:EWTXEdgewise Therapeutics Inc
09/02/202419:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
07/02/202418:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
19/01/202418:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EWTXEdgewise Therapeutics Inc
19/01/202410:37Business WireEdgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common StockNASDAQ:EWTXEdgewise Therapeutics Inc
19/01/202408:04Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:EWTXEdgewise Therapeutics Inc
19/01/202408:02Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EWTXEdgewise Therapeutics Inc
09/01/202410:39Business WireEdgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EWTXEdgewise Therapeutics Inc
19/12/202310:00Business WireEdgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
18/12/202310:00Business WireEdgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy CommunityNASDAQ:EWTXEdgewise Therapeutics Inc
30/11/202310:56Dow Jones NewsEdgewise Gets FDA Orphan, Rare-Pediatric-Disease Designations for Muscular-Dystrophy ProgramNASDAQ:EWTXEdgewise Therapeutics Inc
30/11/202310:00Business WireEdgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDANASDAQ:EWTXEdgewise Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EWTX

Seu Histórico Recente

EU
CDCGR
Caisse Depots Et Consign...
LSE
MAVT
Momentum Multi-asset Value
AMEX
ICOW
Pacer Developed Markets ...
BIT
P1WSP5
NLBNPIT1WSP5 20240920 28...
BIT
I09332
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados